Celularity Inc SEC Filings

CELUW NASDAQ

Welcome to our dedicated page for Celularity SEC filings (Ticker: CELUW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Unraveling Celularity’s SEC disclosures can feel like decoding a lab notebook. Each 10-K packs dense science on placental-derived cell therapy pipelines, manufacturing scale-ups in New Jersey, and revenue from its Lifebank biobanking arm. If you just want to know whether a delayed trial impacts cash burn or how executives price stock options, digging through EDGAR is slow and error-prone.

Stock Titan’s AI transforms those filings into plain-English answers. Need the latest “Celularity quarterly earnings report 10-Q filing” or wonder, “What does Celularity report in their SEC filings?” Our platform streams documents the instant they post, then highlights critical numbers, red-flags risk factors, and links directly to “Celularity 8-K material events explained.” You can even set alerts for “Celularity insider trading Form 4 transactions” to spot buying or selling before headlines.

10-K annual report: Pipeline milestones, segment revenue, GMP facility costs—“Celularity annual report 10-K simplified.”
10-Q quarterly update: Clinical spend trends and cash runway, ideal for “Celularity earnings report filing analysis.”
8-K current report: Trial holds, licensing deals, CFO departures—all “understanding Celularity SEC documents with AI.”
Form 4: “Celularity Form 4 insider transactions real-time” plus historical charts of executive stock moves.
DEF 14A proxy: “Celularity proxy statement executive compensation” distilled into clear tables.

Researchers track manufacturing capacity; portfolio managers monitor “Celularity executive stock transactions Form 4”; biotech analysts compare NK-cell programs across peers. Whatever your angle, our AI-powered summaries, expert context, and real-time feeds keep you ahead—without wading through 200 pages of immunology jargon.

07/16/2025 08:24 AM

Filing

[Form 3] Celularity Inc. Warrant Initial Statement of Beneficial Ownership

Rhea-AI Summary

Celularity Inc. (CELU) – SEC Form 3 filing: Interim CFO Joseph DosSantos has provided his initial statement of beneficial ownership.

Date of event: 06/10/2025
Securities owned: no non-derivative shares reported.
Derivative holding: one employee stock option for 30,000 Class A common shares, exercise price $3.02, expiration 05/01/2034.
Vesting: 25 % after one year from grant; remaining 75 % vest monthly until fully vested on the four-year anniversary, subject to continued service.
Capacity: DosSantos is listed as Interim CFO; filing made individually.

The disclosure is routine and reflects initial alignment of the recently appointed executive with shareholder interests; no immediate financial impact to Celularity’s fundamentals.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[Form 3] Celularity Inc. Warrant Initial Statement of Beneficial Ownership

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Celularity (CELUW)?

The current stock price of Celularity (CELUW) is $0.05 as of July 16, 2025.

What is the primary focus of Celularity Inc?

Celularity Inc focuses on developing placental-derived cell therapies and advanced biomaterials to address significant unmet medical needs in cancer, degenerative diseases, and immune disorders.

How does Celularity generate revenue?

The company operates through three main segments: Cell Therapy, Degenerative Disease, and Bio-banking, with the bio-banking segment generating the majority of its revenue.

What innovative approaches are employed by Celularity in its therapies?

Celularity uses advanced cell engineering techniques including genetic modification of T-cells and NK cells, and leverages a universal receptor approach to combine its cell therapies with approved antibody treatments.

What distinguishes Celularity's cell therapy products?

Celularity’s cell therapy products stand out due to their off-the-shelf, allogeneic nature and their derivation from the readily available postpartum placenta, which provides unique regenerative properties.

In which market segments does Celularity operate?

The company operates in three segments: Cell Therapy, Degenerative Disease, and Bio-banking, each targeting different aspects of regenerative medicine and advanced therapeutics.

What role does the bio-banking segment play for Celularity?

The bio-banking segment is critical as it provides high-quality placental tissues essential for both the company’s research and therapeutic development, and it is the largest revenue contributor.

How is Celularity positioned within the regenerative medicine industry?

Celularity is recognized for its integrated approach, combining advanced biomaterials with innovative cellular therapies, which positions it as a significant contributor to the field of regenerative and cellular medicine.

How does Celularity ensure the quality of its therapies?

The company maintains high standards through rigorous clinical evaluations, in vivo preclinical studies, and a state-of-the-art manufacturing process that supports both research and commercial production.